ω-3脂肪酸乙酯预处理及持续使用减少颈动脉支架术慢血流现象并预防支架内再狭窄
该非随机前瞻性研究纳入2012至2015年100例高脂血症颈动脉狭窄行CAS患者,比较他汀单药与加用ω-3脂肪酸乙酯(DHA 750 mg/d、EPA 1860 mg/d,术前4周起持续至少12个月)的效果。结果显示ω-3脂肪酸组CAS中慢血流现象和12个月支架内再狭窄均显著减少,虚拟组织学显示纤维脂质面积更小、纤维面积更大。
要点
- CAS术前4周起加用ω-3脂肪酸乙酯并持续至少12个月可减少慢血流现象。
- 该方案可显著降低CAS术后12个月支架内再狭窄发生率。
- 低EPA/花生四烯酸比值与症状性病变是易损斑块的相关因素。
核心结论
- ω-3脂肪酸预处理可减少CAS中因斑块易损性产生的慢血流现象。
- 持续每日使用ω-3脂肪酸可抑制CAS术后支架内再狭窄。
研究设计与样本
- 非随机前瞻性试验,回顾性分析历史对照数据。
- 2012至2015年共100例高脂血症颈动脉狭窄行CAS患者,分对照期47例与ω-3脂肪酸期53例。
主要发现
- 虚拟组织学血管内超声显示ω-3脂肪酸期纤维脂质面积显著更小、纤维面积显著更大。
关键数值与推荐
- ω-3脂肪酸乙酯口服剂量为DHA 750 mg/d与EPA 1860 mg/d。
- ω-3脂肪酸从CAS前4周开始,并持续每日使用至少12个月。
临床怎么用
- 对高脂血症颈动脉狭窄行CAS患者,可考虑术前4周起加用ω-3脂肪酸乙酯并持续至少12个月。
- 该方案在他汀治疗基础上可能减少CAS中慢血流现象及术后支架内再狭窄。
局限性
- 研究为非随机前瞻性试验,对照数据为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Carotid artery stenting (CAS) is a less invasive alternative to carotid endarterectomy, but it is essential to prevent thromboembolic complications during CAS and to suppress in-stent restenosis (ISR) after CAS because of the relatively high risk of periprocedural and follow-up stroke events. Clinical trials have demonstrated the strong relationship of carotid plaque vulnerability with the subsequent risk of ipsilateral ischemic stroke and thromboembolic complications during CAS. Recent studies demonstrated that both low eicosapentaenoic acid (EPA) and low docosahexaenoic acid (DHA) levels were significantly associated with lipid-rich coronary and carotid plaques, but little is known about the effect of administration of omega-3 fatty acids (O-3FAs) containing EPA and DHA before and after CAS for stabilizing carotid plaque, preventing thromboembolic complications, and suppressing ISR. In this study, the efficacy of pretreatment with and ongoing daily use of O-3FA in addition to statin treatment was evaluated in patients undergoing CAS. METHODS: This study was a nonrandomized prospective trial with retrospective analysis of historical control data. From 2012 to 2015, there were 100 consecutive patients with hyperlipidemia undergoing CAS for carotid artery stenosis who were divided into two groups. Between 2012 and 2013 (control period), 47 patients were treated with standard statin therapy. Between 2014 and 2015 (O-3FA period), patients were treated with statin therapy and add-on oral O-3FA ethyl esters containing 750 mg/d DHA and 1860 mg/d EPA from 4 weeks before CAS, followed by ongoing daily use for at least 12 months. In all patients, the plaque morphology by virtual histology intravascular ultrasound, the incidence of new ipsilateral ischemic lesions on the day after CAS, the slow-flow phenomenon during CAS, and ISR within 12 months after CAS were compared between the periods. RESULTS: The slow-flow phenomenon during CAS with filter-type embolic protection devices decreased in the O-3FA period (1 of 53 patients [2%]) compared with the control period (7 of 47 patients [15%]; P = .02). Furthermore, ISR for 12 months after CAS was significantly decreased in the O-3FA period (1 of 53 patients [2%]) compared with the control period (10 of 47 patients [21%]; P = .01). On virtual histology intravascular ultrasound analysis, the fibrofatty area was significantly smaller and the fibrous area was significantly greater in the O-3FA period. On multivariate logistic regression analysis, a low EPA/arachidonic acid ratio and a symptomatic lesion were the factors related to vulnerable plaque (P = .01 [odds ratio, 5.24; 95% confidence interval, 1.65-16.63] and P = .01 [odds ratio, 11.72; 95% confidence interval, 2.93-46.86], respectively). CONCLUSIONS: Pretreatment with O-3FA reduces the slow-flow phenomenon generated by plaque vulnerability during CAS, and on-going daily use of O-3FA suppresses ISR after CAS.
引用
- Nakagawa I, Park HS, Yokoyama S, et al. Pretreatment with and ongoing use of omega-3 fatty acid ethyl esters reduce the slow-flow phenomenon and prevent in-stent restenosis in patients undergoing carotid artery stenting. J Vasc Surg. 2017. PMID: 28359716. doi:10.1016/j.jvs.2016.12.132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。